tradingkey.logo

Sophia Genetics SA

SOPH
查看详细走势图
4.800USD
+0.200+4.35%
收盘 02/06, 16:00美东报价延迟15分钟
325.67M总市值
亏损市盈率 TTM

Sophia Genetics SA

4.800
+0.200+4.35%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+4.35%

5天

-8.57%

1月

-4.00%

6月

+50.00%

今年开始到现在

+2.78%

1年

+31.51%

查看详细走势图

TradingKey Sophia Genetics SA股票评分

单位: USD 更新时间: 2026-02-06

操作建议

Sophia Genetics SA当前公司基本面数据相对健康,最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理,在软件与IT服务行业排名152/482位。机构持股占比非常高,近一月多位分析师给出公司评级为强力买入。最高目标价7.33。中期看,股价处于上升通道。近一个月,市场表现较差,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Sophia Genetics SA评分

相关信息

行业排名
152 / 482
全市场排名
259 / 4521
所属行业
软件与IT服务

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

Sophia Genetics SA亮点

亮点风险
SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
业绩高增长
公司营业收入稳步增长,连续3年增长37.03%
业绩增长期
公司处于发展阶段,最新年度总收入65.17M美元
估值低估
公司最新PE估值-4.30,处于3年历史低位
机构减仓
最新机构持股26.90M股,环比减少31.90%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓,最新持仓市值30.80K

分析师目标

根据 4 位分析师
强力买入
评级
7.333
目标均价
+46.67%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Sophia Genetics SA新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Sophia Genetics SA简介

SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
公司代码SOPH
公司Sophia Genetics SA
CEOCamblong (Jurgi)
网址https://www.sophiagenetics.com/
KeyAI